Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection

Abstract Objective To assess the efficacy and safety of intravitreal aflibercept injection in the treatment of CNV secondary to presumed ocular histoplasmosis syndrome (POHS). Purpose To assess safety of intravitreal aflibercept for the treatment of CNV secondary to presumed ocular histoplasmosis sy...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of ophthalmology 2016-04, Vol.51 (2), p.91-96
Main Authors: Walia, Harpreet S., MD, Shah, Gaurav K., MD, Blinder, Kevin J., MD
Format: Article
Language:English
Subjects:
Aged
Angiogenesis Inhibitors - administration & dosage
Choroidal Neovascularization - drug therapy
Choroidal Neovascularization - microbiology
Eye Infections, Fungal - drug therapy
Eye Infections, Fungal - microbiology
Female
Fluorescein Angiography
Histoplasmosis - drug therapy
Histoplasmosis - microbiology
Humans
Internal Medicine
Intravitreal Injections
Male
Middle Aged
Ophthalmology
Prospective Studies
Receptors, Vascular Endothelial Growth Factor - administration & dosage
Recombinant Fusion Proteins - administration & dosage
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Visual Acuity - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective To assess the efficacy and safety of intravitreal aflibercept injection in the treatment of CNV secondary to presumed ocular histoplasmosis syndrome (POHS). Purpose To assess safety of intravitreal aflibercept for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome. Methods Masked, open-label, prospective study. Five subjects will receive 2.0 mg aflibercept injection every 8 weeks with 3 initial monthly doses over a 12 month period. Results No adverse systemic or ocular were reported. At month six, the mean visual acuity improved by 7.8 ETDRS letters, mean central subfoveal thickness decreased by 38.8 microns and mean OCT volume decreased by 0.076 mm3 . At month twelve, the mean visual acuity improved by12.4 ETDRS letters, mean central subfoveal thickness decreased by 34.6 microns and mean OCT volume decreased by 0.576 mm3. Conclusion The use of intravitreal 2.0 mg aflibercept injection for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome yielded no systemic or ocular adverse events and produced improvement in visual acuity and reduction of OCT thickness and volume.
ISSN:0008-4182
1715-3360
DOI:10.1016/j.jcjo.2015.11.007